{
    "nctId": "NCT02129205",
    "briefTitle": "A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors",
    "officialTitle": "A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06650808 IN PATIENTS WITH ADVANCED SOLID TUMORS",
    "overallStatus": "TERMINATED",
    "conditions": "Neoplasms, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Number of Participants With Dose-limiting Toxicities (DLT) (Part 1)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available\n* Previously treated metastatic triple negative breast cancer that expresses Notch3 with at least one measurable lesion\n* Adequate bone marrow, renal and liver function\n\nExclusion Criteria:\n\n* Major surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of starting study treatment\n* Patients with known symptomatic brain metastases requiring steroids\n* Prior treatment with a compound of the same mechanism",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}